The infusion of $175 million into bluebird bio's finances is a positive development, likely to be viewed favorably by investors. It provides the company with a more robust financial foundation, potentially easing cash flow concerns and enabling continued investment in its projects and operations. This financial maneuver could lead to increased investor confidence and a positive short-term impact on the stock price.

Hercules Capital's decision to extend a $175 million loan to bluebird bio underlines its strategy of investing in biotech firms. This move not only demonstrates Hercules Capital's role as a key financier in the biotech sector but also might positively influence its reputation and perceived value among investors. The successful execution and management of this loan could enhance Hercules Capital's standing and potentially have a favorable short-term impact on its stock.